This company listing is no longer active
EC Healthcare Toekomstige groei
Future criteriumcontroles 4/6
EC Healthcare is forecast to grow earnings and revenue by 97.7% and 11.5% per annum respectively. EPS is expected to grow by 97.6% per annum. Return on equity is forecast to be 11.8% in 3 years.
Belangrijke informatie
97.7%
Groei van de winst
97.6%
Groei van de winst per aandeel
Consumer Services winstgroei | 21.9% |
Inkomstengroei | 11.5% |
Toekomstig rendement op eigen vermogen | 11.8% |
Dekking van analisten | Low |
Laatst bijgewerkt | 26 Jul 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2026 | 5,289 | 237 | N/A | 1,170 | 1 |
3/31/2025 | 4,806 | 159 | N/A | 990 | 2 |
3/31/2024 | 4,211 | -19 | 528 | 689 | N/A |
12/31/2023 | 4,157 | -11 | 422 | 709 | N/A |
9/30/2023 | 4,104 | -4 | 317 | 729 | N/A |
6/30/2023 | 3,989 | 33 | 255 | 667 | N/A |
3/31/2023 | 3,875 | 70 | 193 | 605 | N/A |
12/31/2022 | 3,622 | 93 | 162 | 499 | N/A |
9/30/2022 | 3,369 | 117 | 132 | 392 | N/A |
6/30/2022 | 3,144 | 157 | 240 | 500 | N/A |
3/31/2022 | 2,920 | 198 | 348 | 608 | N/A |
12/31/2021 | 2,823 | 253 | 479 | 684 | N/A |
9/30/2021 | 2,727 | 309 | 610 | 760 | N/A |
6/30/2021 | 2,404 | 251 | 541 | 690 | N/A |
3/31/2021 | 2,080 | 193 | 472 | 621 | N/A |
12/31/2020 | 1,854 | 163 | 487 | 597 | N/A |
9/30/2020 | 1,627 | 133 | 503 | 573 | N/A |
6/30/2020 | 1,788 | 210 | 505 | 574 | N/A |
3/31/2020 | 1,949 | 287 | 507 | 576 | N/A |
12/31/2019 | 2,023 | 325 | 273 | 452 | N/A |
9/30/2019 | 2,098 | 364 | 40 | 327 | N/A |
6/30/2019 | 1,975 | 363 | -5 | 283 | N/A |
3/31/2019 | 1,852 | 361 | -49 | 238 | N/A |
12/31/2018 | 1,715 | 355 | 108 | 278 | N/A |
9/30/2018 | 1,578 | 348 | 265 | 317 | N/A |
6/30/2018 | 1,450 | 314 | 269 | 320 | N/A |
3/31/2018 | 1,322 | 279 | 272 | 324 | N/A |
12/31/2017 | 1,253 | 266 | N/A | 302 | N/A |
9/30/2017 | 1,183 | 253 | N/A | 280 | N/A |
6/30/2017 | 1,079 | 227 | N/A | 230 | N/A |
3/31/2017 | 975 | 201 | N/A | 180 | N/A |
12/31/2016 | 878 | 170 | N/A | 123 | N/A |
9/30/2016 | 780 | 139 | N/A | 66 | N/A |
6/30/2016 | 744 | 144 | N/A | 71 | N/A |
3/31/2016 | 708 | 149 | N/A | 76 | N/A |
12/31/2015 | 688 | 166 | N/A | 105 | N/A |
9/30/2015 | 668 | 183 | N/A | 134 | N/A |
6/30/2015 | 645 | 179 | N/A | 146 | N/A |
3/31/2015 | 621 | 174 | N/A | 159 | N/A |
3/31/2014 | 490 | 81 | N/A | 145 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 2138 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Winst versus markt: 2138 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: 2138 is expected to become profitable in the next 3 years.
Omzet versus markt: 2138's revenue (11.5% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
Hoge groei-inkomsten: 2138's revenue (11.5% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 2138's Return on Equity is forecast to be low in 3 years time (11.8%).